Login to Your Account


Price is (almost) right: Immune Design, Pfenex to complete their IPOs

By Randy Osborne
Staff Writer

Friday, July 25, 2014
Companies priced their initial public offerings (IPOs) in two hot therapeutic spaces, immunotherapy and biosimilars, proving that the window remains open – at least for the right candidates, if not at the hoped-for yield. But another firm withdrew its IPO, which could mean tighter times ahead.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription